Dyskinesia is therefore believed to primarily involve chronic over-activation of striatonigral MSNs (67, 68) and there is a wealth of evidence for a particular role of dopamine D1 receptors (D1R) in the development of LID in both patients and pre-clinical models (69–72). The gene discussed is DRD1; the disease is Dyskinesia.